Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 721 AL 735

Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease

Verma A, Chaudhary S, Solanki K, Goyal A, Yadav HN.

Chem Biol Drug Des. 2024 Jan;103(1):e14426. doi: 10.1111/cbdd.14426.

Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer's and Parkinson's Diseases

Ayten Ş, Bilici S.

Curr Nutr Rep. 2024 Jun;13(2):82-96. doi: 10.1007/s13668-024-00539-7. Epub 2024 Apr 23.

Photobiomodulation for Neurodegenerative Diseases: A Scoping Review

Shen Q, Guo H, Yan Y.

Int J Mol Sci. 2024 Jan 28;25(3):1625. doi: 10.3390/ijms25031625.

Methylsulfinyl Hexyl Isothiocyanate (6-MSITC) from Wasabi Is a Promising Candidate for the Treatment of Cancer, Alzheimer's Disease, and Obesity

Bartkowiak-Wieczorek J, Malesza M, Malesza I, Hadada T, Winkler-Galicki J, Grzelak T, Mądry E.

Nutrients. 2024 Aug 1;16(15):2509. doi: 10.3390/nu16152509.

Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease

Ding X, Chen Y, Zhang X, Duan Y, Yuan G, Liu C.

Neuropeptides. 2024 Oct;107:102457. doi: 10.1016/j.npep.2024.102457. Epub 2024 Jul 25.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease

McDowall S, Bagda V, Hodgetts S, Mastaglia F, Li D.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

Hölscher C.

Neuropharmacology. 2024 Aug 1;253:109952. doi: 10.1016/j.neuropharm.2024.109952. Epub 2024 Apr 25.

Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy

Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou JR.

Epigenomics. 2024 Jan;16(1):57-77. doi: 10.2217/epi-2023-0342. Epub 2023 Dec 13.

Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease

Hong CT, Chen JH, Hu CJ.

J Biomed Sci. 2024 Nov 5;31(1):102. doi: 10.1186/s12929-024-01090-x.

The VEGFs/VEGFRs system in Alzheimer's and Parkinson's diseases: Pathophysiological roles and therapeutic implications

Ceci C, Lacal PM, Barbaccia ML, Mercuri NB, Graziani G, Ledonne A.

Pharmacol Res. 2024 Mar;201:107101. doi: 10.1016/j.phrs.2024.107101. Epub 2024 Feb 7.

Limonin (LM) and its derivatives: Unveiling the neuroprotective and anti-inflammatory potential of LM and V-A-4 in the management of Alzheimer's disease and Parkinson's disease

Panda SP, Kesharwani A, Singh M, Kumar S, Mayank, Mallick SP, Guru A.

Fitoterapia. 2024 Oct;178:106173. doi: 10.1016/j.fitote.2024.106173. Epub 2024 Aug 6.

Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection

Chiang MC, Yang YP, Nicol CJB, Wang CJ.

Int J Mol Sci. 2024 Feb 17;25(4):2360. doi: 10.3390/ijms25042360.

Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases

Iyer S, Bhat I, Bangera Sheshappa M.

Mol Nutr Food Res. 2024 Jul;68(13):e2300409. doi: 10.1002/mnfr.202300409. Epub 2024 Mar 15.

Biomarkers for Managing Neurodegenerative Diseases

Cheslow L, Snook AE, Waldman SA.

Biomolecules. 2024 Mar 26;14(4):398. doi: 10.3390/biom14040398.

Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: Focusing on Alzheimer's disease and Parkinson's disease

Li Y, Zhang J, Ma B, Yu W, Xu M, Luan W, Yu Q, Zhang L, Rong R, Fu Y, Cao H.

Int J Pharm. 2024 Dec 5;666:124786. doi: 10.1016/j.ijpharm.2024.124786. Epub 2024 Oct 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias